Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | CKS1B | P61024 | 9/20 | 0.35 |
| ▸ | SKP1 | P63208 | 9/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 9/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320708 | 0.77 | PDE10A (0.43) | — | |
| SCHEMBL16003617 | 0.76 | KDM4E (0.43) | CKS1BSKP1SKP2CYP46A1HPGD | |
| SCHEMBL16003610 | 0.74 | CKS1B (0.58) | CKS1BSKP1SKP2USP30KMT2A | |
| SCHEMBL16320666 | 0.73 | CKS1B (0.41) | CKS1BSKP1SKP2USP30CYP46A1 | |
| SCHEMBL16320993 | 0.73 | PDE10A (0.47) | HPGD | |
| SCHEMBL16320986 | 0.72 | PDE10A (0.42) | GPR119MEN1KMT2APDK2 | |
| SCHEMBL16003590 | 0.72 | CKS1B (0.45) | CKS1BSKP1SKP2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16320264 | 0.71 | CKS1B (0.44) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL16320826 | 0.68 | — | — | |
| SCHEMBL16340802 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | GPR119 484/4885CKS1B 2123/4885SKP1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.